Navigation Links
Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
Date:5/16/2012

RIDGEFIELD, Conn., May 16, 2012 /PRNewswire/ -- Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.  LUX-Lung 3, which compares the investigational oral, once-daily therapy, afatinib, to pemetrexed/cisplatin, is the largest Phase III trial to date in first-line EGFR mutation-positive, advanced, metastatic NSCLC patients, and the first to use pemetrexed/cisplatin as a comparator in this population.

The presentation of the LUX-Lung 3 trial will shed light on a distinct and specific NSCLC patient population, those with EGFR mutations.  EGFR mutations occur in 10 to 15 percent of NSCLC patients, and are well-established predictive biomarkers that provide specific targets for therapeutic intervention in NSCLC.  TitleLead AuthorPresentation detailsLUX-Lung 3: A randomized,
open-label, phase III study of
afatinib versus pemetrexed and
cisplatin as first-line treatment for
patients with advanced
adenocarcinoma of the lung
harboring EGFR-activating mutations.

 

James Chih-Hsin Yang, MD, PhD

 

 

 

Oral Abstract #LBA7500

Date: Monday, June 4
Time: 3:00 PM-3:15 PM CDT

 

 

 "We are excited to share the results of our pivotal LUX-Lung 3 trial, the largest and most robust ever conducted in EGFR mutation-positive patients," said Berthold Greifenberg, M.D., Vice President, Clinical Development and Medical Affairs, Oncology, Boehringer Ingelheim Pharmaceuticals, Inc.  "We are continuously advancing the development of our oncology pipeline and look forward to opportunities to contribute to the bo
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... YORK , May 22, 2013 While ... their teens, friends to drink at home under adult ... about drinking, the truth is that there are serious ... Partnership at Drugfree.org and The Treatment Research ... new, interactive web resource for parents and caregivers to ...
(Date:5/22/2013)... 2013 PRNewswire – iBio, Inc. (NYSE ... vaccine candidate for the newly emerged H7N9 influenza ... the iBioLaunch™ platform. This validation milestone was achieved ... sequence information to purification of recombinant protein. ... The iBioLaunch platform eliminates the need to ...
(Date:5/22/2013)... 22, 2013 WomanCare Global recently launched ... an extensive training initiative attended by 90 health ... ) (Logo: http://photos.prnewswire.com/prnh/20101018/DC83896LOGO ) Simplant, ... highly effective subdermal implant composed of two thin, ... (a synthetic form of the hormone progestin). These ...
Breaking Medicine Technology:Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 2Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 3Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 4Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 5Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 6Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 7iBio Technology Produces Vaccine Candidate for Recently Emerged H7N9 Influenza 2WomanCare Global launches Simplant, Long-acting Reversible Contraception, in Chile 2
... SAN DIEGO, Feb. 3, 2011 Neurocrine Biosciences, Inc. (Nasdaq: ... report its fourth quarter and year-end 2010 financial results after ... will then host a live conference call and webcast to ... afternoon, February 10, 2011 at 5:00 p.m. Eastern Time (2:00 ...
... 2011 SkinMedica, Inc., the fastest-growing professional skin ... that it is introducing a new, fast-acting anti-redness ... in over two decades.  It is the first ... visible redness.     (Photo: ...
Cached Medicine Technology:SkinMedica Launches Redness Relief CalmPlex™ 2SkinMedica Launches Redness Relief CalmPlex™ 3
(Date:5/22/2013)... , , TUESDAY, May 21 (HealthDay News) -- The overall ... in 10 people either overweight or obese and large ... or not exercising, a new government report shows. , ... Control and Prevention, the report found Americans continuing to ... to soaring rates of heart disease, diabetes and other ...
(Date:5/22/2013)... Teams who focus on productivity, process, quality, ... Do-Done StepTracker whiteboard as a rallying point for project ... display the current status of our company-wide lean initiatives ... is listed down the side and the milestones are ... squares are filled with yellow circles. Turning the magnets ...
(Date:5/22/2013)... Paris, France: Results from a large observational ... whether bivalirudin is superior to heparin in ... 30-day mortality in patients with non-ST segment ... coronary intervention (PCI)., European and US NSTE-ACS ... alternative to unfractionated heparin plus GP IIb/IIIa ...
(Date:5/22/2013)... 22, 2013 The PreDiabetes Center ... in the Greater Philadelphia Tour de Cure, a premier cycling ... are passionate about stopping the spread of diabetes , ... , The Tour de Cure will take place Saturday, ... Road in Ambler, 30 minutes outside of Philadelphia, between the ...
(Date:5/22/2013)... New York City, New York (PRWEB) May 22, 2013 ... Black American: Causes, Culture, Consequences, and Cost ” article published ... on obesity is fully justified. The Centers for Disease ... of U.S. adults aged 20 and over are overweight, 35.7% ... alarming facts are highlighted in this investigative article. In particular, ...
Breaking Medicine News(10 mins):Health News:Americans Still Making Unhealthy Choices: CDC 2Health News:Americans Still Making Unhealthy Choices: CDC 3Health News:Project Managers Organize Manufacturing Projects and Training with the New Steptracker Project Status Magnetic Whiteboards 2Health News:Registry questions superiority of bivalirudin over heparin 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 3Health News:Black American Obesity Examined In The Latest FinancesOnline.com Article 2Health News:Black American Obesity Examined In The Latest FinancesOnline.com Article 3
... Dr. Eric Olson, chairman of molecular biology at UT ... France,s prestigious Lefoulon-Delalande Foundation Grand Prize for his work ... The prize has an international reputation as the ... about $664,000 (500,000 euros) will be presented June 10 ...
... , LOUISVILLE, Colo., June 4 /PRNewswire/ -- ... 13 GHXcellence Awards for achievements in improving supply chain performance. ... a recognition ceremony in Nashville at the 9th Annual GHX ... focused on both the buy and sell side of the ...
... The Minneapolis-St. Paul office of Weber Shandwick has been ... the organization,s largest annual awareness campaign. The "Be The ... to reach a diverse audience of current and potential ... with leukemia and other life-threatening diseases, a marrow transplant ...
... to Reduce Administrative Costs in Healthcare and Streamlines Processes ... N.J., June 4 MD On-Line Inc ... core focus of converting paper submitting providers to electronic ... Corp. (MCC) of Bristol, CT. Both are EHNAC-accredited ...
... nursing homes with one in four residents carrying the bacteria, a ... Its authors say that the findings, which have been ... highlight the need for infection control strategies to be given a ... be the largest of its kind studying MRSA in private nursing ...
... Fitness and Nutrition Program from Fitness Expert Monique Hollowell ... often feel their bodies will never be the same ... a fit pregnancy, less painful birth and quick recovery ... and personal trainer, Monique Hollowell has created a fitness ...
Cached Medicine News:Health News:UT Southwestern's Olson wins prestigious French award for heart research 2Health News:GHXcellence Awards Honor Healthcare Providers and Suppliers for Achievements in Supply Chain Performance 2Health News:GHXcellence Awards Honor Healthcare Providers and Suppliers for Achievements in Supply Chain Performance 3Health News:Weber Shandwick Chosen By National Marrow Donor Program(R) To Head Awareness Campaign 2Health News:Weber Shandwick Chosen By National Marrow Donor Program(R) To Head Awareness Campaign 3Health News:MD On-Line Inc. Acquires Medical Claim Corp. 2Health News:1 in 4 nursing home residents carry MRSA 2Health News:Keys to a Fit Pregnancy and Losing the Baby Weight 2Health News:Keys to a Fit Pregnancy and Losing the Baby Weight 3
EnTrust family of ICDs provides a suite of features for total AT/AF co-morbidity management, including diagnostics to detect when your patient develops AT/AF, and both termination and intervention th...
... Medical is the world leader in ... used worldwide for permanent pacemaker and ... and port implantation, and for temporary ... St. Jude Medical Peel-Away introducers includes ...
... Stent System combines low-profile, high radial force, and ... wire compatible stent system provides 6F sheath / ... - 10.0 mm). Now, with longer stents available, ... stent lengths (28, 38, 56, 80 and 100 ...
... transseptal left heart catheterization occurs when the ... a sheath with an alternate curve while ... an exchange has required a repeat septal ... has overcome this problem with the unique ...
Medicine Products: